The Pharma Data

SEPTEMBER 7, 2021

KEYTRUDA plus 5-FU and cisplatin reduced the risk of death by 27% (HR=0.73 [95% CI, 0.62-0.86]; KEYTRUDA plus 5-FU and cisplatin reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.55-0.76]; 0.86]; p<0.0001). The median OS was 12.4 months (95% CI, 10.5-14.0) months (95% CI, 8.8-10.8) 0.76]; p<0.0001).

HR 52

HR Packaging Packaging Trials 52

The Pharma Data

AUGUST 30, 2021

KEYTRUDA in combination with chemotherapy (pac, nab-paclitaxel or gem/carbo) reduced the risk of disease progression or death by 35% (HR=0.65 [95% CI, 0.49, 0.86]; p=0.0012), with a median PFS of 9.7 months (95% CI, 7.6-11.3) months (95% CI, 5.3-7.5), 7.5), versus the same chemotherapy regimens alone in these patients. months [95% CI, 5.4-32.4]

Hormones 52

Hormones HR Trials Protein 52

Pfizer

AUGUST 15, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Drugs 99

Drugs Vaccine Vaccination In-Vitro 99

Pfizer

DECEMBER 13, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Drugs 110

Drugs Licensing Licensing Production 110

Pfizer

DECEMBER 20, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Drugs 69

Drugs Licensing Licensing Containment 69

The Pharma Data

JUNE 18, 2021

months; hazard ratio [HR] 0.33 [95% CI 0.25-0.45]); with chlorambucil in combination with obinutuzumab (Obi-Clb; HR 0.85, 95% CI [0.54-1.35]; 7 VENCLEXTA (venetoclax) [Package Insert]. After a median follow-up of more than four years (52.4 0.45]); results are descriptive. with Ven-Obi versus 83.1% 1.35]; P=0.49). AbbVie Inc.

Medicine 40

Medicine HR Trials Production 40

Pfizer

JANUARY 27, 2023

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. The dose for patients with moderate renal impairment (eGFR ≥30 to For more information, please visit www.PAXLOVID.com.

Marketing 75

Marketing Production Drugs Licensing 75

The Pharma Data

DECEMBER 29, 2020

one-sided), as seronegative patients treated with the antibody cocktail had a lower risk of death or receiving mechanical ventilation (HR: 0.78; 80% CI: 0.51-1.2). The results passed the futility analysis (p<0.3 At day 5, the relative reduction compared to placebo was -1.1 log 10 copies/mL (nominal p=0.002 for combined doses).

Antibody 52

Antibody Trials Production Clinical Trials 52

The Pharma Data

MARCH 20, 2021

The inactivated virus samples were digested with trypsin and analyzed on a high resolution Orbitrap Eclipse mass spectrometer interfaced with an RSLCnano system using a 3 hr gradient. SARS-CoV-2 nucleocapsid is highly expressed during infection ( 22 ) and a potential target for viral detection by mass spectrometry.

Protein 52

Protein Antibody Development RNA 52

The Pharma Data

JUNE 18, 2021

The study met its primary endpoint of superior progression-free survival (PFS) as assessed by an independent review committee (IRC) with a HR 0.216 (95% CI, 0.131-0.357; p < 0.0001), demonstrating a reduction in the risk of disease progression or death for I+V of approximately 78% compared to C+O. vs. 11.4%) (p < 0.0001). Chicago, IL.:

Medicine 52

Medicine Production FDA Approval Trials 52

Pfizer

NOVEMBER 23, 2022

One carton contains five blister packs of PAXLOVID, as co-packaged nirmatrelvir tablets with ritonavir tablets, providing all required doses for a full five-day treatment course. PAXLOVID is generally administered at a dose of 300 mg (two 150 mg tablets) of nirmatrelvir with one 100 mg tablet of ritonavir, given twice-daily for five days.

Licensing 40

Licensing Licensing Drugs Manufacturing 40

XTalks

AUGUST 2, 2023

2) Paxlovid (nirmatrelvir/ritonavir) Paxlovid is a dual-packaged oral medication for the treatment of COVID-19. 5) Ibrance (palbociclib) Ibrance is a chemotherapy drug indicated for hormone receptor positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer. for a 2-pen package (0.6

Sales 98

Sales Manufacturing FDA Approval Life Science 98

Pharmaceutical Technology

MARCH 21, 2023

Based on the individual contract, these CMOs manufacture small molecules or biological active pharmaceutical ingredients (APIs), as well as packaging material, and are charged with other related functions. Sharp Packaging Services is producing the solid dose of the drug and packaging it.

Manufacturing 147

Manufacturing Drugs Packaging Packaging 147

XTalks

NOVEMBER 26, 2024

for a 120-count package of 140 mg capsules. Date of first FDA approval: February 3, 2015 Disease(s) it is FDA-approved to treat: Ibrance is a kinase inhibitor used for treating hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer. billion in global sales in 2023.

Sales 105

Sales FDA Approval Drugs Marketing 105